Structure-based redesign of proteins for minimal T-cell epitope content

Area of Science:

• Protein engineering and immunology
• Computational biology and drug design

Background:

• Therapeutic proteins can elicit T-cell immune responses, limiting their clinical use.
• Current methods like epitope deletion address only a limited number of immunogenic sites.

Purpose of the Study:

• To develop a novel computational method for designing deimmunized proteins.
• To create proteins that are native-like but possess minimal immunogenic epitopes.

Main Methods:

• Extended the Rosetta protein design software with an epitope scoring function.
• Incorporated constraints to guide the redesign process towards reduced immunogenicity.
• Benchmarked the method on diverse protein panels and applied it to therapeutic targets.

Main Results:

• Deimmunized protein designs exhibited minimal predicted immunogenic epitope content.
• Designed proteins maintained native-like structural and quality characteristics.
• Achieved native sequence recovery comparable to non-deimmunized protein designs.

Conclusions:

• The 'bottom-up' protein redesign approach effectively minimizes immunogenicity while preserving protein structure.
• This method offers a promising strategy for developing safer and more effective protein-based therapeutics.